Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pre-Eclampsia | 11 | 2019 | 1200 | 1.250 |
Why?
|
Pregnancy, Animal | 4 | 2016 | 134 | 0.650 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 6 | 2019 | 552 | 0.640 |
Why?
|
Puerperal Disorders | 1 | 2019 | 275 | 0.580 |
Why?
|
Placental Circulation | 1 | 2012 | 40 | 0.420 |
Why?
|
Placenta | 5 | 2019 | 1698 | 0.400 |
Why?
|
Kidney Transplantation | 9 | 2018 | 4251 | 0.380 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2016 | 489 | 0.360 |
Why?
|
Receptors, Erythropoietin | 1 | 2010 | 147 | 0.350 |
Why?
|
Kidney Failure, Chronic | 8 | 2018 | 2538 | 0.350 |
Why?
|
Cardiomyopathies | 2 | 2019 | 1912 | 0.350 |
Why?
|
Ventricular Remodeling | 1 | 2016 | 1224 | 0.320 |
Why?
|
Proteinuria | 4 | 2017 | 658 | 0.290 |
Why?
|
Reproduction | 1 | 2012 | 668 | 0.290 |
Why?
|
Glomerulonephritis | 2 | 2018 | 372 | 0.280 |
Why?
|
Neovascularization, Physiologic | 3 | 2012 | 1351 | 0.270 |
Why?
|
Erythropoietin | 1 | 2010 | 726 | 0.260 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2073 | 0.250 |
Why?
|
Hemodynamics | 2 | 2012 | 4199 | 0.250 |
Why?
|
Smoke | 3 | 2010 | 227 | 0.240 |
Why?
|
Drug Resistance | 1 | 2010 | 1609 | 0.230 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 2635 | 0.230 |
Why?
|
Aldosterone | 3 | 2013 | 877 | 0.230 |
Why?
|
Pregnancy | 16 | 2019 | 29144 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2013 | 3508 | 0.200 |
Why?
|
Kidney Glomerulus | 3 | 2018 | 697 | 0.190 |
Why?
|
Endotoxemia | 3 | 2011 | 207 | 0.190 |
Why?
|
Complement Activation | 2 | 2019 | 453 | 0.180 |
Why?
|
Renin-Angiotensin System | 3 | 2013 | 759 | 0.180 |
Why?
|
Angiopoietin-2 | 2 | 2012 | 173 | 0.180 |
Why?
|
Receptor, TIE-2 | 2 | 2011 | 178 | 0.170 |
Why?
|
Nephrotic Syndrome | 3 | 2007 | 389 | 0.160 |
Why?
|
Peripartum Period | 1 | 2019 | 133 | 0.160 |
Why?
|
Complement Factor H | 1 | 2018 | 110 | 0.160 |
Why?
|
Kidney | 5 | 2017 | 7186 | 0.160 |
Why?
|
Delayed Graft Function | 1 | 2017 | 48 | 0.150 |
Why?
|
HLA-DQ Antigens | 1 | 2018 | 210 | 0.150 |
Why?
|
Glomerulonephritis, IGA | 1 | 2017 | 66 | 0.150 |
Why?
|
Histocompatibility Testing | 1 | 2018 | 741 | 0.140 |
Why?
|
Angiotensin II | 2 | 2016 | 881 | 0.130 |
Why?
|
Complement Pathway, Classical | 1 | 2015 | 97 | 0.130 |
Why?
|
Fibrinogen | 1 | 2018 | 894 | 0.130 |
Why?
|
Podocytes | 2 | 2017 | 396 | 0.130 |
Why?
|
Saliva | 2 | 2009 | 809 | 0.130 |
Why?
|
Complement C4b | 1 | 2015 | 135 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2019 | 1184 | 0.120 |
Why?
|
Cytomegalovirus | 1 | 2018 | 732 | 0.120 |
Why?
|
Graft Survival | 3 | 2018 | 3737 | 0.120 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2016 | 689 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2017 | 599 | 0.110 |
Why?
|
Internationality | 1 | 2018 | 1003 | 0.110 |
Why?
|
Fetal Resorption | 1 | 2012 | 17 | 0.110 |
Why?
|
Litter Size | 1 | 2012 | 54 | 0.110 |
Why?
|
NAD | 1 | 2016 | 593 | 0.100 |
Why?
|
Cytomegalovirus Infections | 1 | 2018 | 820 | 0.100 |
Why?
|
Aldehydes | 2 | 2010 | 167 | 0.100 |
Why?
|
Acute Kidney Injury | 2 | 2016 | 1972 | 0.100 |
Why?
|
Female | 30 | 2019 | 380194 | 0.100 |
Why?
|
Endothelium, Vascular | 4 | 2013 | 4456 | 0.100 |
Why?
|
Graft Rejection | 3 | 2018 | 4397 | 0.100 |
Why?
|
Salivary Proteins and Peptides | 1 | 2010 | 53 | 0.090 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2012 | 349 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2015 | 5097 | 0.090 |
Why?
|
Placentation | 1 | 2010 | 82 | 0.090 |
Why?
|
Carotid Arteries | 1 | 2015 | 952 | 0.090 |
Why?
|
Protein Modification, Translational | 1 | 2009 | 21 | 0.090 |
Why?
|
Reactive Nitrogen Species | 1 | 2009 | 35 | 0.090 |
Why?
|
Multiple Organ Failure | 1 | 2012 | 390 | 0.090 |
Why?
|
Salivary alpha-Amylases | 1 | 2009 | 16 | 0.090 |
Why?
|
Follistatin-Related Proteins | 1 | 2009 | 48 | 0.090 |
Why?
|
Renal Dialysis | 3 | 2010 | 1786 | 0.090 |
Why?
|
Opportunistic Infections | 2 | 2002 | 389 | 0.090 |
Why?
|
STAT5 Transcription Factor | 1 | 2010 | 259 | 0.090 |
Why?
|
Tissue Donors | 1 | 2018 | 2240 | 0.080 |
Why?
|
Mice, Inbred Strains | 1 | 2012 | 1827 | 0.080 |
Why?
|
alpha-Amylases | 1 | 2008 | 41 | 0.080 |
Why?
|
Pregnancy Trimester, First | 2 | 2010 | 853 | 0.080 |
Why?
|
Angiopoietin-1 | 1 | 2009 | 114 | 0.080 |
Why?
|
Angiogenic Proteins | 1 | 2009 | 104 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1855 | 0.080 |
Why?
|
Endotoxins | 1 | 2011 | 527 | 0.080 |
Why?
|
Carotid Artery Diseases | 1 | 2015 | 882 | 0.080 |
Why?
|
Regional Blood Flow | 1 | 2012 | 1525 | 0.080 |
Why?
|
K562 Cells | 1 | 2010 | 634 | 0.080 |
Why?
|
Blood Flow Velocity | 1 | 2012 | 1423 | 0.080 |
Why?
|
Pregnancy Proteins | 1 | 2009 | 229 | 0.080 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2012 | 500 | 0.080 |
Why?
|
Molecular Weight | 1 | 2010 | 2255 | 0.080 |
Why?
|
Infant, Small for Gestational Age | 1 | 2010 | 440 | 0.070 |
Why?
|
Postoperative Complications | 3 | 2018 | 15295 | 0.070 |
Why?
|
Membrane Proteins | 3 | 2010 | 7880 | 0.070 |
Why?
|
Humans | 38 | 2019 | 744343 | 0.070 |
Why?
|
Tyrosine | 1 | 2010 | 1461 | 0.070 |
Why?
|
Lung Injury | 1 | 2011 | 436 | 0.070 |
Why?
|
Enalapril | 1 | 2007 | 327 | 0.070 |
Why?
|
Blotting, Western | 2 | 2011 | 5179 | 0.070 |
Why?
|
Animals | 18 | 2016 | 168757 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1182 | 0.060 |
Why?
|
Trans-Activators | 2 | 2012 | 2924 | 0.060 |
Why?
|
Mice | 12 | 2016 | 81183 | 0.060 |
Why?
|
Recovery of Function | 1 | 2015 | 2925 | 0.060 |
Why?
|
Spironolactone | 1 | 2007 | 382 | 0.060 |
Why?
|
Fetus | 1 | 2012 | 1880 | 0.060 |
Why?
|
Nitric Oxide | 2 | 2010 | 2132 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 2 | 2010 | 2038 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2007 | 1518 | 0.060 |
Why?
|
Hyperhomocysteinemia | 1 | 2004 | 124 | 0.060 |
Why?
|
Phosphorylation | 2 | 2016 | 8436 | 0.060 |
Why?
|
Vitamin B 6 | 1 | 2004 | 237 | 0.050 |
Why?
|
Hydrocortisone | 1 | 2010 | 1826 | 0.050 |
Why?
|
Fever of Unknown Origin | 1 | 2002 | 93 | 0.050 |
Why?
|
Leptin | 1 | 2010 | 1599 | 0.050 |
Why?
|
Cell Line | 3 | 2013 | 15997 | 0.050 |
Why?
|
Male | 24 | 2018 | 350118 | 0.050 |
Why?
|
Mucormycosis | 1 | 2002 | 97 | 0.050 |
Why?
|
Esophagitis | 1 | 2002 | 152 | 0.050 |
Why?
|
Sepsis | 2 | 2012 | 2593 | 0.050 |
Why?
|
Signal Transduction | 4 | 2016 | 23403 | 0.050 |
Why?
|
Vitamin B 12 | 1 | 2004 | 527 | 0.050 |
Why?
|
Dinoprostone | 2 | 2016 | 600 | 0.050 |
Why?
|
Transcription Factors | 3 | 2016 | 12208 | 0.050 |
Why?
|
Lamivudine | 1 | 2001 | 342 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2010 | 3200 | 0.040 |
Why?
|
Diabetes, Gestational | 1 | 2009 | 1184 | 0.040 |
Why?
|
HELLP Syndrome | 1 | 2019 | 41 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2007 | 2915 | 0.040 |
Why?
|
Herpes Simplex | 1 | 2002 | 470 | 0.040 |
Why?
|
Middle Aged | 13 | 2018 | 213383 | 0.040 |
Why?
|
Complement Pathway, Alternative | 1 | 2018 | 126 | 0.040 |
Why?
|
Biopsy | 3 | 2018 | 6756 | 0.040 |
Why?
|
Disease Models, Animal | 5 | 2016 | 18029 | 0.040 |
Why?
|
Dialysis | 1 | 2017 | 75 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 4420 | 0.040 |
Why?
|
Adult | 15 | 2019 | 214055 | 0.040 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2001 | 615 | 0.040 |
Why?
|
Mitochondria | 3 | 2017 | 3520 | 0.040 |
Why?
|
Cold Ischemia | 1 | 2018 | 65 | 0.040 |
Why?
|
Trophoblasts | 1 | 2019 | 215 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8642 | 0.040 |
Why?
|
Mice, Inbred C57BL | 5 | 2016 | 21827 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10943 | 0.040 |
Why?
|
Telomerase | 1 | 2002 | 730 | 0.040 |
Why?
|
Hypertension | 3 | 2015 | 8480 | 0.040 |
Why?
|
Glutathione | 2 | 2010 | 589 | 0.040 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2011 | 3336 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2018 | 684 | 0.040 |
Why?
|
HLA-DR Antigens | 1 | 2018 | 645 | 0.030 |
Why?
|
Recurrence | 2 | 2018 | 8340 | 0.030 |
Why?
|
Blood Pressure | 4 | 2016 | 8554 | 0.030 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2016 | 87 | 0.030 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2016 | 255 | 0.030 |
Why?
|
Hepatitis B | 1 | 2001 | 695 | 0.030 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2016 | 86 | 0.030 |
Why?
|
Angiotensins | 1 | 2016 | 151 | 0.030 |
Why?
|
Complement Factor D | 1 | 2015 | 68 | 0.030 |
Why?
|
Hypertension, Pulmonary | 1 | 2006 | 1537 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2010 | 3143 | 0.030 |
Why?
|
Albuminuria | 2 | 2010 | 682 | 0.030 |
Why?
|
Mannose-Binding Lectins | 1 | 2015 | 100 | 0.030 |
Why?
|
Logistic Models | 1 | 2010 | 13408 | 0.030 |
Why?
|
Cell Division | 1 | 2002 | 4568 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2018 | 57776 | 0.030 |
Why?
|
Mutation | 1 | 2018 | 29786 | 0.030 |
Why?
|
Niacinamide | 1 | 2016 | 417 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2010 | 4262 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 3 | 2013 | 8301 | 0.030 |
Why?
|
Lipopolysaccharides | 2 | 2011 | 2216 | 0.030 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2013 | 20 | 0.030 |
Why?
|
Rats | 4 | 2013 | 24260 | 0.030 |
Why?
|
Adrenal Cortex | 1 | 2013 | 140 | 0.030 |
Why?
|
Phenotype | 1 | 2010 | 16365 | 0.030 |
Why?
|
Survival Analysis | 2 | 2017 | 10252 | 0.030 |
Why?
|
Bromocriptine | 1 | 2012 | 111 | 0.030 |
Why?
|
Complement System Proteins | 1 | 2015 | 795 | 0.030 |
Why?
|
Mice, 129 Strain | 1 | 2012 | 386 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2015 | 881 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2019 | 21746 | 0.030 |
Why?
|
Inflammation | 1 | 2011 | 10638 | 0.030 |
Why?
|
Endothelium-Dependent Relaxing Factors | 1 | 2010 | 19 | 0.020 |
Why?
|
6-Ketoprostaglandin F1 alpha | 1 | 2010 | 83 | 0.020 |
Why?
|
Prognosis | 3 | 2018 | 29063 | 0.020 |
Why?
|
Survival Rate | 2 | 2018 | 12788 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 2170 | 0.020 |
Why?
|
Aged | 6 | 2018 | 163280 | 0.020 |
Why?
|
Natriuresis | 1 | 2010 | 124 | 0.020 |
Why?
|
Pedigree | 1 | 2018 | 4644 | 0.020 |
Why?
|
Netherlands | 1 | 2015 | 2170 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2187 | 0.020 |
Why?
|
Antiviral Agents | 2 | 2018 | 2987 | 0.020 |
Why?
|
Telemetry | 1 | 2011 | 205 | 0.020 |
Why?
|
Nitrosation | 1 | 2009 | 26 | 0.020 |
Why?
|
Glucose | 1 | 2002 | 4397 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4186 | 0.020 |
Why?
|
Diagnostic Techniques, Endocrine | 1 | 2009 | 45 | 0.020 |
Why?
|
Amino Acids | 1 | 2016 | 1736 | 0.020 |
Why?
|
Catechin | 1 | 2009 | 66 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2002 | 4149 | 0.020 |
Why?
|
Mice, Obese | 1 | 2010 | 424 | 0.020 |
Why?
|
Cyclic GMP | 1 | 2010 | 409 | 0.020 |
Why?
|
Kidney Tubules, Proximal | 1 | 2011 | 416 | 0.020 |
Why?
|
Cohort Studies | 3 | 2018 | 40561 | 0.020 |
Why?
|
Skin | 1 | 2002 | 4364 | 0.020 |
Why?
|
Receptors, Leptin | 1 | 2010 | 360 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2017 | 6365 | 0.020 |
Why?
|
Postpartum Period | 1 | 2015 | 1086 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2016 | 1403 | 0.020 |
Why?
|
Luminescence | 1 | 2008 | 137 | 0.020 |
Why?
|
Antidotes | 1 | 2008 | 138 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2007 | 191 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1799 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2009 | 405 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7149 | 0.020 |
Why?
|
Capillary Permeability | 1 | 2011 | 798 | 0.020 |
Why?
|
Enzyme Inhibitors | 2 | 2010 | 3798 | 0.020 |
Why?
|
Pregnancy Trimester, Second | 1 | 2010 | 732 | 0.020 |
Why?
|
Ischemia | 1 | 2016 | 1907 | 0.020 |
Why?
|
Electrolytes | 1 | 2007 | 282 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2011 | 1878 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2012 | 14557 | 0.020 |
Why?
|
Cyclic AMP | 1 | 2010 | 1472 | 0.020 |
Why?
|
Models, Animal | 1 | 2013 | 2171 | 0.020 |
Why?
|
Enalaprilat | 1 | 2005 | 10 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2804 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2013 | 19229 | 0.020 |
Why?
|
Thiazepines | 1 | 2005 | 30 | 0.020 |
Why?
|
Glucose Intolerance | 1 | 2009 | 577 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2010 | 1730 | 0.020 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2005 | 192 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2016 | 3086 | 0.020 |
Why?
|
Endothelin-1 | 1 | 2006 | 314 | 0.020 |
Why?
|
Morbidity | 1 | 2010 | 1769 | 0.020 |
Why?
|
DNA | 1 | 2018 | 7301 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2016 | 3279 | 0.010 |
Why?
|
Cardiac Output | 1 | 2006 | 854 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12245 | 0.010 |
Why?
|
Drug Synergism | 1 | 2007 | 1792 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2009 | 3701 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4751 | 0.010 |
Why?
|
Vascular Resistance | 1 | 2006 | 936 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2012 | 1637 | 0.010 |
Why?
|
Losartan | 1 | 2005 | 299 | 0.010 |
Why?
|
Mycophenolic Acid | 1 | 2005 | 343 | 0.010 |
Why?
|
Vasoconstrictor Agents | 1 | 2006 | 642 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2007 | 11366 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8089 | 0.010 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 284 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 7729 | 0.010 |
Why?
|
Echocardiography, Doppler | 1 | 2006 | 935 | 0.010 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 451 | 0.010 |
Why?
|
Down-Regulation | 1 | 2009 | 3002 | 0.010 |
Why?
|
Acyclovir | 1 | 2002 | 272 | 0.010 |
Why?
|
Vasodilator Agents | 1 | 2006 | 977 | 0.010 |
Why?
|
Ultrasonography | 1 | 2015 | 5985 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 2455 | 0.010 |
Why?
|
Cytokines | 1 | 2016 | 7322 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2005 | 2505 | 0.010 |
Why?
|
Esophagoscopy | 1 | 2002 | 390 | 0.010 |
Why?
|
Homocysteine | 1 | 2004 | 647 | 0.010 |
Why?
|
Risk Factors | 3 | 2018 | 72290 | 0.010 |
Why?
|
Monocytes | 1 | 2010 | 2596 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2010 | 6622 | 0.010 |
Why?
|
Culture Media | 1 | 2002 | 908 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 2503 | 0.010 |
Why?
|
Chronic Disease | 1 | 2015 | 9146 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2938 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2017 | 77449 | 0.010 |
Why?
|
Cell Survival | 1 | 2009 | 5882 | 0.010 |
Why?
|
Heart | 1 | 2012 | 4467 | 0.010 |
Why?
|
Doxorubicin | 1 | 2005 | 2234 | 0.010 |
Why?
|
Living Donors | 1 | 2002 | 620 | 0.010 |
Why?
|
Pulmonary Artery | 1 | 2006 | 1912 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2002 | 1850 | 0.010 |
Why?
|
Calcinosis | 1 | 2006 | 1499 | 0.010 |
Why?
|
Folic Acid | 1 | 2004 | 1300 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|
Lipids | 1 | 2007 | 3305 | 0.010 |
Why?
|
Time Factors | 2 | 2009 | 40075 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23338 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2011 | 13033 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2016 | 63114 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2010 | 16689 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.010 |
Why?
|
Pyridines | 1 | 2005 | 2825 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10481 | 0.010 |
Why?
|
Prospective Studies | 2 | 2010 | 53288 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 15540 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 56430 | 0.010 |
Why?
|
Fibroblasts | 1 | 2002 | 4161 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2010 | 25625 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2010 | 25043 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 12951 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2010 | 13695 | 0.000 |
Why?
|
Heart Failure | 1 | 2007 | 10900 | 0.000 |
Why?
|
Neoplasms | 1 | 2010 | 21683 | 0.000 |
Why?
|